pomalidomide + lenalidomide

Pomalidomide and lenalidomide are both oral immunomodulatory agents (IMiDs) used primarily in the treatment of multiple myeloma. Both drugs are structural analogs of thalidomide and act as cereblon E3 ligase modulators. Their mechanisms include direct anti-myeloma activity through proteasomal degradation of Ikaros and Aiolos transcription factors, inhibition of angiogenesis, modulation of immune responses (upregulation of interferon gamma, IL-2 and IL-10; downregulation of IL-6), interaction with bone marrow stromal cells, and indirect effects on the tumor microenvironment[4][6]. Pomalidomide is typically used after disease progression on lenalidomide-containing regimens[4][5]. Both drugs are approved for use in relapsed/refractory multiple myeloma—lenalidomide as a first-line or maintenance therapy; pomalidomide for patients who have received at least two prior therapies including lenalidomide[5].

Other names

thalidomide analogsimmunomodulatory drugs